Venous Thromboembolism Taskforce Audit Program

Sanofi8,764 enrolled

Overview

To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates. To determine the proportion of medically admitted patients with risk factors for VTE. To assess and compare the use of venous thromboembolism (VTE) prophylaxis in hospitalized medical patients versus recommendations and current guidelines. To determine the patient characteristics of those deemed to be at risk of VTE. To determine the proportion of patients receiving appropriate thromboprophylaxis for their risk. To determine the type and duration (where possible) of prophylaxis used.

Study Type

OBSERVATIONAL

Enrollment

8,764

Conditions

Venous Thrombosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hospital admission for an acute illness with an in-patient hospital stay of 3 days or more. Exclusion Criteria: * Patients who have undergone any type of surgery during current admission * Patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit. * Prior enrollment in this protocol during current admission * Prior enrollment in a VTE study involving pharmaceutical or mechanical treatment within last 90 days. * Admission for suspected or diagnosed deep vein thrombosis The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis

Macquarie Park, Australia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.